DiaMedica Therapeutics Inc.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$32.8M
- Total assets
- $61.4M
- Market cap
- $303.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $34.4M
- Operating income
- -$34.4M
- Income tax
- $28.0K
- Net income
- -$32.8M
- EPS (basic)
- $-0.70
Balance sheet
- Total assets
- $61.4M
- Current assets
- $60.6M
- Total liabilities
- $5.3M
- Current liabilities
- $5.1M
- Shareholders’ equity
- $56.1M
Cash flow
- Operating cash flow
- -$29.1M
- Investing cash flow
- -$2.2M
- Financing cash flow
- $43.9M
- Net cash flow
- $12.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $303.9M
- Shares outstanding
- 54.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 29, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $32.8M.
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review DiaMedica Therapeutics Inc..
Write a review
News about DiaMedica Therapeutics Inc.
News & sentiment via Polygon.io
